Patient-friendly option presents challenge to Soliris and Ultomiris

10 August 2022

Efforts on the part of Swiss pharma giant Roche (ROG: SIX) to take on AstraZeneca (LSE: AZN) in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) advanced a step this week.

Since buying Alexion Pharma, AstraZeneca has held the trump cards in tackling PNH, a rare and life-threatening disease of the blood which causes the destruction of cells and marrow.

With Soliris (eculizumab) and Ultomiris (ravulizumab), the company now owns an intravenously-administered treatment franchise which has delivered multi-billion dollar revenues for its former owner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK